

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/001167-2024>

Tender

Provision of Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) All Ages, All Indications including Paediatric Neuro-Oncology SRS/SRT Services

NHS England

F02: Contract notice

Notice identifier: 2024/S 000-001167

Procurement identifier (OCID): ocds-h6vhtk-042ce3

Published 12 January 2024, 4:35pm

Section I: Contracting authority

I.1) Name and addresses

NHS England

Quarry House, Quarry Hill

Leeds

LS2 7UE

Contact

Surinder Kahlon

Email

surinder.kahlon@nhs.net

Country

United Kingdom

Region code

UK - United Kingdom

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://health-family.force.com/s/Welcome>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://health-family.force.com/s/Welcome>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Provision of Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) All Ages, All Indications including Paediatric Neuro-Oncology SRS/SRT Services

II.1.2) Main CPV code

- 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

NHS Arden and Greater East Midlands Commissioning Support unit on behalf of NHS England wish to procure under Lots four All Tiers Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) all ages, including paediatric oncology services covering England.

SRS/SRT are methods of delivering doses of precisely targeted intracranial radiotherapy treatment and used for a wide range of malignant and benign intracranial conditions, as set out

within NHS England clinical commissioning policy. This comprises Tier 1-2 indications of cerebral metastases, non-skull base meningiomas, skull base tumours including Vestibular

Schwannoma and meningioma, pituitary adenoma, and the Tier 3-4 indications including arteriovenous malformations, trigeminal neuralgia and paediatric CNS tumours. The prevalence of these conditions varies from less than one per 100,000 population to up to 30 per 100,000.

The two Service Specification include a tiered service model, based on clinical indication prevalence and complexity and groups together more common, less complex conditions (called Tier 1&2) and less common and more complex conditions (called Tier 3&4).

The two service specification, cover:

- (i) Tier 1 & 2 indications for adults; and
- (ii) All tiers, all ages and all conditions as this better reflects service provision and

pathways.

This procurement is focused on the ALL Tiers, all ages Service Specification ONLY.

The Lots will cover the whole of England based on the following Geographies:

1. Lot 1: North England and North West England
2. Lot 2: South Yorkshire and Midlands
3. Lot 3: Greater London, East of England and South England
4. Lot 4: South West of England

II.1.5) Estimated total value

Value excluding VAT: £83,500,000

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

II.2) Description

II.2.1) Title

Lot 1 North England and North West England

Lot No

1

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The objective of this procurement is to commission four Lots All Tiers Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) all ages, including paediatric oncology services covering England. The eligibility criteria, lotting structure and scope of services are detailed in this document. Bidders must be located within the Lot geography for which they are bidding. Bidders are only required to deliver the Tier 1 and 2 services within the geographical catchment area served by the neurosurgical service in

which they are based and not for the whole Lot geography.

On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.

In order to be eligible, bidders must ensure that:

- a) The Service is delivered as part of an integrated neurosurgical and oncology service located within the same geographical area or city serving a population of at least 2 million in order to generate 100 SRS/SRT Tier 1&2 cases per year.
- b) The Service is delivered as part of an integrated paediatric neurosurgical and oncology service, commissioned to provide Paediatric Photon Radiotherapy located within the same geographical area or city to a Children's Cancer Principal Treatment Centre (PTC)
- c) The neurosurgical centre must host the full range of specialist intracranial Multi-disciplinary Teams (MDT) for all clinical indications for adult and paediatric intracranial tumours, namely, combined Neurosciences Brain and Central Nervous System (CNS) MDT, and / or the individual neuro-oncology MDTs, skull base MDT, and pituitary MDT, neuro-vascular MDT and Paediatric oncology MDTs as listed in Table 1.2.
- d) The Service must deliver the complete range of SRS/SRT treatments including paediatric oncology indications (Table 1.2) and participate in the full range of specialist neurosurgical MDTs and generate a minimum annual activity volume of: (i) 100 SRS/SRT Tier 1 and Tier 2 cases; plus (ii) circa 200 Tier 3 and Tier 4 (combined) cases.

SRS/SRT are methods of delivering doses of precisely targeted intracranial radiotherapy treatment and used for a wide range of malignant and benign intracranial conditions, as set-out within NHS England clinical commissioning policy. This comprises Tier 1-2 indications of cerebral metastases, non-skull base meningiomas, skull base tumours including Vestibular Schwannoma and meningioma, pituitary adenoma, and the Tier 3-4 indications including arteriovenous malformations, trigeminal neuralgia and paediatric CNS tumours. The prevalence of these conditions varies from less than one per 100,000 population to up to 30 per 100,000.

This tiered service model is based on clinical indication prevalence and complexity and groups together more common, less complex conditions (called Tier 1&2) and less common and more complex conditions (called Tier 3&4).

The two service specifications, cover:

- (i) Tier 1 & 2 indications for adults; and
- (ii) All tiers, all ages and all conditions as this better reflects service provision and pathways.

This procurement is focused on the ALL Tiers, all ages Service Specification ONLY.

The Lots will cover the whole of England based on the following Geographies:

1. Lot 1: North England and North West England
2. Lot 2: South Yorkshire and Midlands
3. Lot 3: Greater London, East of England and South England
4. Lot 4: South West of England

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £20,725,500

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 October 2024

End date

30 September 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

Bidders will be required to adhere to the recommendations detailed in the NPSA report 'Towards Safety in Radiotherapy' and will be required to meet the Pre-Assessment Radiotherapy Quality Assurance Requirements by June 2024 at the latest. Bidders will be required to complete external Radiotherapy Quality Assurance (RTTQA) prior to contract award.

On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.

The duration of this contract will be for a period of 5 years with the Commissioner having the option to extend the Contract for up to a further two years. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice. The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal:

<https://health-family.force.com/s/Welcome>
(<https://health-family.force.com/s/Welcome>)

The reference is C220364 and the closing date for completed ITT responses is 12:00pm, midday on Friday 23rd February 2024. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 13:00pm on Thursday 25th January 2024. If you would like to participate in this event, please email:

josselin.canevet@nhs.net

by Wednesday 24th January 2024. All slides and questions and responses will be made available to all bidders following the event.

II.2) Description

II.2.1) Title

Lot 2 South Yorkshire and Midlands

Lot No

2

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The objective of this procurement is to commission four Lots All Tiers Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) all ages, including paediatric oncology services covering England. The eligibility criteria, lotting structure and scope of services are detailed in this document. Bidders must be located within the Lot geography for which they are bidding. Bidders are only required to deliver the Tier 1 and 2 services within the geographical catchment area served by the neurosurgical service in which they are based and not for the whole Lot geography.

On completion of the procurement process, NHS England will complete a Market

Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.

In order to be eligible, bidders must ensure that:

- a) The Service is delivered as part of an integrated neurosurgical and oncology service located within the same geographical area or city serving a population of at least 2 million in order to generate 100 SRS/SRT Tier 1&2 cases per year.
- b) The Service is delivered as part of an integrated paediatric neurosurgical and oncology service, commissioned to provide Paediatric Photon Radiotherapy located within the same geographical area or city to a Children's Cancer Principal Treatment Centre (PTC)
- c) The neurosurgical centre must host the full range of specialist intracranial Multi-disciplinary Teams (MDT) for all clinical indications for adult and paediatric intracranial tumours, namely, combined Neurosciences Brain and Central Nervous System (CNS) MDT, and / or the individual neuro-oncology MDTs, skull base MDT, and pituitary MDT, neuro-vascular MDT and Paediatric oncology MDTs as listed in Table 1.2.
- d) The Service must deliver the complete range of SRS/SRT treatments including paediatric oncology indications (Table 1.2) and participate in the full range of specialist neurosurgical MDTs and generate a minimum annual activity volume of: (i) 100 SRS/SRT Tier 1 and Tier 2 cases; plus (ii) circa 200 Tier 3 and Tier 4 (combined) cases.

SRS/SRT are methods of delivering doses of precisely targeted intracranial radiotherapy treatment and used for a wide range of malignant and benign intracranial conditions, as set-out within NHS England clinical commissioning policy. This comprises Tier 1-2 indications of cerebral metastases, non-skull base meningiomas, skull base tumours including Vestibular Schwannoma and meningioma, pituitary adenoma, and the Tier 3-4 indications including arteriovenous malformations, trigeminal neuralgia and paediatric CNS tumours. The prevalence of these conditions varies from less than one per 100,000 population to up to 30 per 100,000.

This tiered service model is based on clinical indication prevalence and complexity and groups together more common, less complex conditions (called Tier 1&2) and less common and more complex conditions (called Tier 3&4).

The two service specifications, cover:

- (i) Tier 1 & 2 indications for adults; and
- (ii) All tiers, all ages and all conditions as this better reflects service provision and pathways.

This procurement is focused on the ALL Tiers, all ages Service Specification ONLY.

The Lots will cover the whole of England based on the following Geographies:

1. Lot 1: North England and North West England
2. Lot 2: South Yorkshire and Midlands
3. Lot 3: Greater London, East of England and South England
4. Lot 4: South West of England

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £23,041,600

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 October 2024

End date

30 September 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

Bidders will be required to adhere to the recommendations detailed in the NPSA report 'Towards Safety in Radiotherapy' and will be required to meet the Pre-Assessment Radiotherapy Quality Assurance Requirements by June 2024 at the latest. Bidders will be required to complete external Radiotherapy Quality Assurance (RTTQA) prior to contract award.

On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.

The duration of this contract will be for a period of 5 years with the Commissioner having the option to extend the Contract for up to a further two years. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice. The ITT

documentation including a questionnaire is available through the Atamis (Health Family) portal:

<https://health-family.force.com/s/Welcome>
(<https://health-family.force.com/s/Welcome>)

The reference is C220364 and the closing date for completed ITT responses is 12:00pm, midday on Friday 23rd February 2024. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 13:00pm on Thursday 25th January 2024. If you would like to participate in this event, please email:

josselin.canevet@nhs.net

by Wednesday 24th January 2024. All slides and questions and responses will be made available to all bidders following the event.

II.2) Description

II.2.1) Title

Lot 3 Greater London, East of England and South England

Lot No

3

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The objective of this procurement is to commission four Lots All Tiers Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) all ages, including paediatric oncology services covering England. The eligibility criteria, lotting structure and scope of services are detailed in this document. Bidders must be located within the Lot geography for which they are bidding. Bidders are only required to deliver the Tier 1 and 2 services within the geographical catchment area served by the neurosurgical service in which they are based and not for the whole Lot geography.

On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.

In order to be eligible, bidders must ensure that:

- a) The Service is delivered as part of an integrated neurosurgical and oncology service

located within the same geographical area or city serving a population of at least 2 million in order to generate 100 SRS/SRT Tier 1&2 cases per year.

b) The Service is delivered as part of an integrated paediatric neurosurgical and oncology service, commissioned to provide Paediatric Photon Radiotherapy located within the same geographical area or city to a Children's Cancer Principal Treatment Centre (PTC)

c) The neurosurgical centre must host the full range of specialist intracranial Multi-disciplinary Teams (MDT) for all clinical indications for adult and paediatric intracranial tumours, namely, combined Neurosciences Brain and Central Nervous System (CNS) MDT, and / or the individual neuro-oncology MDTs, skull base MDT, and pituitary MDT, neuro-vascular MDT and Paediatric oncology MDTs as listed in Table 1.2.

d) The Service must deliver the complete range of SRS/SRT treatments including paediatric oncology indications (Table 1.2) and participate in the full range of specialist neurosurgical MDTs and generate a minimum annual activity volume of: (i) 100 SRS/SRT Tier 1 and Tier 2 cases; plus (ii) circa 200 Tier 3 and Tier 4 (combined) cases.

SRS/SRT are methods of delivering doses of precisely targeted intracranial radiotherapy treatment and used for a wide range of malignant and benign intracranial conditions, as set-out within NHS England clinical commissioning policy. This comprises Tier 1-2 indications of cerebral metastases, non-skull base meningiomas, skull base tumours including Vestibular Schwannoma and meningioma, pituitary adenoma, and the Tier 3-4 indications including arteriovenous malformations, trigeminal neuralgia and paediatric CNS tumours. The prevalence of these conditions varies from less than one per 100,000 population to up to 30 per 100,000.

This tiered service model is based on clinical indication prevalence and complexity and groups together more common, less complex conditions (called Tier 1&2) and less common and more complex conditions (called Tier 3&4).

The two service specifications, cover:

- (i) Tier 1 & 2 indications for adults; and
- (ii) All tiers, all ages and all conditions as this better reflects service provision and pathways.

This procurement is focused on the ALL Tiers, all ages Service Specification ONLY.

The Lots will cover the whole of England based on the following Geographies:

1. Lot 1: North England and North West England
2. Lot 2: South Yorkshire and Midlands
3. Lot 3: Greater London, East of England and South England
4. Lot 4: South West of England

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £24,818,400

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 October 2024

End date

30 September 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

Bidders will be required to adhere to the recommendations detailed in the NPSA report 'Towards Safety in Radiotherapy' and will be required to meet the Pre-Assessment Radiotherapy Quality Assurance Requirements by June 2024 at the latest.

Bidders will be required to complete external Radiotherapy Quality Assurance (RTTQA) prior to contract award.

On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.

The duration of this contract will be for a period of 5 years with the Commissioner having the option to extend the Contract for up to a further two years. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice. The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal:

<https://health-family.force.com/s/Welcome>
(<https://health-family.force.com/s/Welcome>)

The reference is C220364 and the closing date for completed ITT responses is 12:00pm, midday on Friday 23rd February 2024. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 13:00pm on Thursday 25th January 2024. If you would like to participate in this event, please email:

josselin.canevet@nhs.net

by Wednesday 24th January 2024. All slides and questions and responses will be made available to all bidders following the event.

II.2) Description

II.2.1) Title

Lot 4 South West of England

Lot No

4

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UK - United Kingdom

II.2.4) Description of the procurement

The objective of this procurement is to commission four Lots All Tiers Stereotactic Radiosurgery / Radiotherapy (SRS /SRT) Services – (Intracranial) all ages, including paediatric oncology services covering England. The eligibility criteria, lotting structure and scope of services are detailed in this document. Bidders must be located within the Lot geography for which they are bidding. Bidders are only required to deliver the Tier 1 and 2 services within the geographical catchment area served by the neurosurgical service in which they are based and not for the whole Lot geography.

On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.

In order to be eligible, bidders must ensure that:

- a) The Service is delivered as part of an integrated neurosurgical and oncology service located within the same geographical area or city serving a population of at least 2 million in order to generate 100 SRS/SRT Tier 1&2 cases per year.
- b) The Service is delivered as part of an integrated paediatric neurosurgical and oncology service, commissioned to provide Paediatric Photon Radiotherapy located within the

same geographical area or city to a Children's Cancer Principal Treatment Centre (PTC)

c) The neurosurgical centre must host the full range of specialist intracranial Multi-disciplinary Teams (MDT) for all clinical indications for adult and paediatric intracranial tumours, namely, combined Neurosciences Brain and Central Nervous System (CNS) MDT, and / or the individual neuro-oncology MDTs, skull base MDT, and pituitary MDT, neuro-vascular MDT and Paediatric oncology MDTs as listed in Table 1.2.

d) The Service must deliver the complete range of SRS/SRT treatments including paediatric oncology indications (Table 1.2) and participate in the full range of specialist neurosurgical MDTs and generate a minimum annual activity volume of: (i) 100 SRS/SRT Tier 1 and Tier 2 cases; plus (ii) circa 200 Tier 3 and Tier 4 (combined) cases.

SRS/SRT are methods of delivering doses of precisely targeted intracranial radiotherapy treatment and used for a wide range of malignant and benign intracranial conditions, as set-out within NHS England clinical commissioning policy. This comprises Tier 1-2 indications of cerebral metastases, non-skull base meningiomas, skull base tumours including Vestibular Schwannoma and meningioma, pituitary adenoma, and the Tier 3-4 indications including arteriovenous malformations, trigeminal neuralgia and paediatric CNS tumours. The prevalence of these conditions varies from less than one per 100,000 population to up to 30 per 100,000.

This tiered service model is based on clinical indication prevalence and complexity and groups together more common, less complex conditions (called Tier 1&2) and less common and more complex conditions (called Tier 3&4).

The two service specifications, cover:

- (i) Tier 1 & 2 indications for adults; and
- (ii) All tiers, all ages and all conditions as this better reflects service provision and pathways.

This procurement is focused on the ALL Tiers, all ages Service Specification ONLY.

The Lots will cover the whole of England based on the following Geographies:

1. Lot 1: North England and North West England
2. Lot 2: South Yorkshire and Midlands
3. Lot 3: Greater London, East of England and South England
4. Lot 4: South West of England

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £14,940,400

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

1 October 2024

End date

30 September 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

Bidders will be required to adhere to the recommendations detailed in the NPSA report 'Towards Safety in Radiotherapy' and will be required to meet the Pre-Assessment Radiotherapy Quality Assurance Requirements by June 2024 at the latest.

Bidders will be required to complete external Radiotherapy Quality Assurance (RTTQA) prior to contract award.

On completion of the procurement process, NHS England will complete a Market Engagement exercise scheduled, to follow the outcome from this procurement process for the remaining Tier 1 & Tier 2 services which will be open to all bidders.

The duration of this contract will be for a period of 5 years with the Commissioner having the option to extend the Contract for up to a further two years. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice. The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal:

<https://health-family.force.com/s/Welcome>

<https://health-family.force.com/s/Welcome>

The reference is C220364 and the closing date for completed ITT responses is 12:00pm, midday on Friday 9th 23rd February 2024. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 13:00pm on Thursday 25th January

2024. If you would like to participate in this event, please email:

josselin.canevet@nhs.net

by Wednesday 24th January 2024. All slides and questions and responses will be made available to all bidders following the event.

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

23 February 2024

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Tender must be valid until: 23 February 2024

IV.2.7) Conditions for opening of tenders

Date

23 February 2023

Local time

12:00pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

NHS Arden and GEM CSU

St John's House, East Street

Leicester

LE1 6NB

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>

VI.4.2) Body responsible for mediation procedures

NHS Arden and GEM CSU

St John's House, East Street

Leicester

LE1 6NB

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>

VI.4.4) Service from which information about the review procedure may be obtained

NHS Arden and GEM CSU

St John's House, East Street

Leicester

LE1 6NB

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>